Histology was distributed as follows: SCC in 91 (62.8%) patients (well/moderately differentiated in 31 [21.4%] cases, poorly differentiated in 60 [41.4%]), SNC not otherwise specified (SNCNOS) in 30 (20.7%), NEC in 10 (6.9%), high-grade NITAC (HG-NITAC) in 6 (4.1%), SNUC without molecular identifier in 5 (3.4%), and SMARCB1/INI1-deficient carcinoma (ID-SNUC) in 3 (2.1%) (Figure 1). The gene discussed is SMARCB1; the disease is neuroendocrine carcinoma.